TH109959A - Short-acting, bioactive peptides for cellular and immune modulation. - Google Patents

Abstract

DC60 (28/03/51) A peptide which has four to fourteen resins. Will be revealed to be bioactive These peptides will It consists of a short chunk of HB-107 peptide (SEQ ID NO I), which itself is a chunk of the zecropin B antimicrobial protein, and exhibits stimulating properties, cell mobility. And anti-inflammatory As the curatinocyte is particularly sensitive to this effect, the peptides disclosed here It constitutes a useful substance for the medical treatment of skin injuries, for example from diabetic eczema. Moreover, peptides are effective in preventing and reversing the damage of Skin surface as a result of the destruction of various environment Importantly, the therapeutic effect of the peptide is evident at concentrations equal to or greater than the HB-107 peptide, and therefore is a less expensive, more versatile approach. For development Effective therapeutic agents Methods for the production and use of these peptides are Also disclosed: drug patents

Claims (3)

Disclaimer (all) which will not appear on the advertisement page: Edit 03/07/2019 No disclaimer. -------------------------------------------------- ---------------------------- Revised 03/04/2019 Page 1 of number 2 Page Disclaimer 1. ----- -------------------------------------------------- --------------------------------------------- ----- -06/12/2018 ------ (OCR) Page 1 of 2 Pages Claim 1. 2. Peptide according to claim 1, where (0 peptide will include Either way, or both L- and D- amino acids inantiomers (ii) peptides that are conjugated to carrier molecules, amide added or are Add lipid (iii) methionine, valine, lysine, or glutamate residue to the amino end of the peptide (iv) lysine, valine. , Glycine, or asparagene residue are at the carboxy end of the peptide or (v) any rod combination of (i) - (iv) 1. 1., 1. 1. 1. 8. The composition consists of at least one of the following items: 1 - 7, and the pharmaceutical acceptable carrier page 2 of the number 2 9. Composition according to claim 8, where peptides are available in concentrations ranging from 0.1 μg / mL. Up to 50 mcg / ml Or 0.1 μg / ml. Up to 20 mcg / ml 1 0. Composition according to claim 8, where the mixture is in the form of aerosol, emulsion, liquid, lotion, fumigation, slurry, wax, powder or foam 1 1. 1 1. 1. 1 3. Elements according to claim 12 where the wound affects the skin or involves tissue. Mucous mucus of such mammals 1 4. Composition according to claim 12, where wounds are wounds due to abrasions, blisters, burns, necrosis, necrotic wounds, bruises. , Rash, scars, or the result of aging Or environmental conditions 1 1. ------------ ------ 30/01/2018 ------ (OCR) Page 1 of the number 2 pages Claim 1 . 2. Peptide according to claim 1, where (i) the peptide is composed of either one or both L- and D- amino acids inantiomers. (Ii) peptides that are conjugated with carrier molecules, amide-loaded or lipid-added (iii) methionine, valine, lysine, or glutamate. The residue is at the amino end of the peptide (iv). Lysine, valine, glycine, or asparagene. Residew is at the carboxy end of the peptide. Tide or (v) any combination of (i) - (iv) 1. 1., 1. 1. 1. 8. The composition consists of at least a few tides according to any clause. Clause 1-7 and pharmaceutical-acceptable carrier page 2 of the number 2. Page 9. Composition according to claim 8, where peptides are present in concentrations in the range of 0.1 μg. /ml. Up to 50 mcg / ml Or 0.1 μg / ml. Up to 20 mcg / ml 1 0. Composition according to claim 8, where the mixture is in the form of aerosol, emulsion, liquid, lotion, krem, slurry, wax, powder or foam 1 1. 1 1 1 3. Elements according to claim 12 where the wound affects the skin or involves tissue. Mucus of mammals 1 4. Composition according to claim 12, where wounds are wounds due to abrasions, blisters, burns, necrosis, sores, bruises, Rashes, scars, or the result of aging Or environmental effects 1 1. 20 ------------ 1. 2. Peptide according to claim 1, where the peptide will be in any way One or both L- and D- amino acids inanthiomers 3. Peptides according to claim 1, where the peptide is conjugated to the carrier molecule, is added. Amide group Or was added to lipids 4. peptide according to claim 1, where methionine, valine, lysine, or glutamate residue is at the end of the amino 5. Peptides according to claim 1, where lysine, valine, glycine, or asparagene residue are at the carboxy end 1. 1. 1. 1.1 1. 1 1.1 2. Peptide according to claim 1, where the order of the peptide is SEQ ID NO: 3 1 1. 1 1. 1 5. Composition consisting of at least one peptide as Any 1-14 claim Pharmacy-approved vehicles 1 6. Composition according to claim 15, where peptides are available in concentrations ranging from approximately 0.1 μg / mL. Up to about 50 mic g / ml 1 7. Composition according to claim 15, where peptides are present in concentrations ranging from approximately 0.1 μg / mL. Up to approx. 20 μg / ml 1 8. Composition according to claim 15, where the composition shall be aerosol, emulsion, liquid, lotion, cream, slurry, wax, powder or foam 1 1.1. 2 0. Rights 15 where such elements are used for wound healing in Mammals When used in therapeutic doses For a period with a result of 2 1. Composition according to claim 20, where the wound affects the skin or mucous tissue that Involvement of the aforementioned mammals 2 2. Composition according to claim 20, where the wound is due Abrasions, blisters, burns, wounds Torn, eczema, bruises, rashes, scars, or results from aging Or exposure to the environment 2 3. Composition according to claim 20, where therapeutic effect quantity of the component is Contains peptides at concentrations that range from approximately 0.1 μg / mL to approximately 50 μg / mL. 2 1.1.